Sage Therapeutics Inc. said its experimental drug Sage-217 received the U.S. Food and Drug Administration's breakthrough therapy designation to treat depression.
The Cambridge, Mass.-based biotechnology company said the regulator's decision was primarily based on data from a phase 2 trial, which met its main goal.
The designation will help expedite development and regulatory review of the drug.
SAGE-217 is also being developed for Parkinson's disease and sleep disorders.
